



IWGDF Guidelines – Disclosure of interest form

Name: Bijan Najafi

Affiliation: University of California, Los Angeles

Position: Full Professor

IWGDF Working Group: Prevention

For the following items, please disclose any interest from the past five years that might be perceived by others as potentially influencing your judgment in any topic in the IWGDF Guideline(s) that you contribute to.

- Ancillary positions:

Served as a consultant for Mölnlycke on wound dressing-related topics.

Served as a consultant for BioSensics LLC on topics related to dementia and aging in place.

- Personal financial interests: None

- Personal relations (this includes personal relations or relations via close family that might be perceived by others as potentially influencing your judgment):

None

- Externally funded research (this includes research funding awarded to you as project member, or to your department, for funding that might be perceived by others as potentially influencing your judgment). If yes, name the title/topic of the grant.

Federal Funding

1. **NIH R01DK124789** (Armstrong & Najafi)
Agency: *National Institutes of Health (NIH)*
Title: *Improving the Science of Adherence Reinforcement and Safe Mobility in People with Diabetic Foot Ulcers Using Smart Offloading*
Role: Principal Investigator (PI)
2. **NIH R43AG082614**
Agency: *National Institutes of Health (NIH)*
Title: *Tele-FootX: Virtually Supervised Tele-Exercise Platform for Accelerating Plantar Wound Healing*
Description: This project aims to develop a device that delivers an interactive, game-based foot and ankle exercise program to support wound healing in people with diabetic foot ulcers, in collaboration with BioSensics LLC.
Role: Principal Investigator (PI)

3. **NIH R43AG082614** (Najafi & Joshi)
Agency: *National Institutes of Health (NIH)*
Title: *Tele-Sox: A Telemedicine Solution Based on Wearables and Gamification to Prevent Venous Thromboembolism in Oncology Geriatric Patients*
Description: This Phase I SBIR project aims to develop a device that delivers an interactive, game-based foot and ankle exercise program to prevent venous thromboembolism (VTE), in collaboration with Stexol LLC.
Role: Principal Investigator (PI)
 4. **NIH R43AG060868-01** (Schoess)
Agency: *National Institutes of Health (NIH)*
Title: *Exercise Evaluation and Recovery Therapy (EXERT)*
Description: The purpose of this study is to design and validate a wearable platform to detect early signs of pain during exercise among patients with painful lower extremity claudication, in collaboration with Eden Inc.
Role: Co-Investigator
 5. **DoD W81XWH-21-1-0616**
Agency: *United States Army Medical Research*
Title: *Developing an Ideal Wound Care Platform – Transforming Powder Dressing for Diabetic Foot Ulcer Treatment*
Major Goals: Evaluate the incidence of wound closure in patients with diabetic foot ulcers after 12 weeks of treatment using Altrazeal and standard wound therapies, in collaboration with Altrazeal Company.
Role: Principal Investigator (PI)
-

Industrial Funding

6. **EO2 (Private Company)**
Title: *Evaluation of Oxypur Wound Dressing with Transcu O₂ for Surgical Incisions*
Role: Principal Investigator (PI)
Description: This study examines the effectiveness of continuous oxygen therapy in enhancing outcomes for surgically closed wounds.
7. **AVAZZIA (Private Company)**
Title: *Electrical Stimulation as an Adjunctive Therapy to Accelerate Wound Healing in People with Diabetes and Plantar Ulcers – A Randomized Controlled Trial*
Role: Principal Investigator (PI)
Description: This study evaluates the effectiveness of electrical stimulation in accelerating wound healing.
8. **Orthofeet (Private Company)**
Title: *A Prospective Proof-of-Concept Trial to Evaluate the Efficacy, Acceptability, and Perception of Benefit of an Innovative Pain Relief Footwear*
Major Goals: Conduct a clinical study to assess the short- and intermediate-term benefits

and effectiveness of a novel pain relief footwear, *Orthofeet*.

Role: Principal Investigator (PI)

- Other disclosures:

None

When you have nothing to disclose, please state here:

Signature and date:

Feb, 26, 2025

A handwritten signature in dark ink, reading "B. Nagel". The signature is written in a cursive style with a large, looped "B" and a stylized "Nagel".